You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
McKesson
Harvard Business School
AstraZeneca
Medtronic

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Claims for Patent: 5,856,442

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,856,442
Title: Transcripts of the MHC class I HLA-G gene and their applications
Abstract:Transcripts of the major histocompatibility complex (MHC) Class I HLA-G gene which are present in foetal trophoblasts and/or in adult circulating mono-nuclear cells, as well as methods of using these. Either the said transcripts comprise, in succession in the 5\' to 3\' direction: a fragment encoding the signal peptide (exon 1), a fragment encoding the .alpha.1 domain (exon 2), a fragment encoding the .alpha.2 domain (exon 3), a fragment encoding the transmembrane TM domain (exon 5), a fragment encoding the cytoplasmic domain (exon 6) and the 3\' untranslated fragment (exon 8), which sequence is designated HLA-G4, or the said transcripts comprise intron 4.
Inventor(s): Carosella; Edgardo Delfino (Paris, FR), Moreau; Philippe (Viry-Chatillon, FR), Gluckman; Eliane (Paris, FR), Kirszenbaum; Marek (Orsay, FR)
Assignee: Commissariat a l\'Energie Atomique (Paris, FR)
Application Number:08/406,057
Patent Claims:1. A protein encoded by a transcript of the human MHC HLA-G gene, wherein said transcript comprises in succession from the 5' end to the 3' end:

a sequence encoding the .alpha.2 domain;

a sequence encoding the transmembrane domain; and

a sequence encoding the cytoplasmic domain;

said transcript not containing a sequence encoding the .alpha.3 domain.

2. The protein of claim 1, wherein said transcript additionally comprises:

a sequence encoding the signal peptide located on the 5' side of said sequence encoding the .alpha.2 domain;

a sequence encoding the .alpha.1 domain located between said sequence encoding the signal peptide and said sequence encoding the .alpha.2 domain; and

a sequence encoding the 3' untranslated region located on the 3' side of said sequence encoding the cytoplasmic domain.

3. A polypeptide which has the amino acid sequence of SEQ ID NO:7.

4. The protein of claim 1, wherein said transcript additionally comprises:

a sequence encoding the 3' untranslated region located on the 3' side of said sequence encoding the cytoplasmic domain.

5. The protein of claim 4, wherein said transcript has the nucleotide sequence of SEQ ID NO:1.

6. The protein of claim 1, wherein said transcript additionally comprises:

a sequence encoding the signal peptide located on the 5' side of said sequence encoding the .alpha.2 domain; and

a sequence encoding the .alpha.1 domain located between said sequence encoding the signal peptide and said sequence encoding the transmembrane domain.

7. A protein encoded by a transcript of the human MHC HLA-G gene, wherein said transcript comprises in succession from the 5' end to the 3' end:

a sequence encoding the signal peptide;

a sequence encoding the .alpha.1 domain;

a sequence encoding the .alpha.3 domain;

intron 4; and

a sequence encoding the transmembrane domain.

8. The protein of claim 7, wherein said transcript additionally comprises:

a sequence encoding the .alpha.2 domain located between said sequence encoding the .alpha.1 domain and said a sequence encoding the .alpha.3 domain;

a sequence encoding the cytoplasmic domain located on the 3' side of said sequence encoding the transmembrane domain; and

a sequence encoding the 3' untranslated region located on the 3' side of said sequence encoding the cytoplasmic domain.

9. A polypeptide having the amino acid sequence of SEQ ID NO:8.

10. The protein of claim 7, wherein said transcript additionally comprises:

a sequence encoding the cytoplasmic domain located on the 3' side of said sequence encoding the transmembrane domain; and

a sequence encoding the 3' untranslated region located on the 3' side of said sequence encoding the cytoplasmic domain.

11. A polypeptide which has the amino acid sequence of SEQ ID NO:9.

12. The protein of claim 7, wherein said transcript additionally comprises:

a sequence encoding the .alpha.2 domain located between said sequence encoding the .alpha.1 domain and said a sequence encoding the .alpha.3 domain; and

a sequence encoding the 3' untranslated region located on the 3' side of said sequence encoding transmembrane domain.

13. The peptide of claim 7, wherein said transcript additionally comprises:

a sequence encoding the .alpha.2 domain located between said sequence encoding the .alpha.1 domain and said a sequence encoding the .alpha.3 domain.

14. A composition, comprising the protein of claim 1 and a carrier.

15. A composition, comprising the protein of claim 7 and a carrier.

16. A method for producing an antibody, comprising the step of immunizing an animal with the protein of claim 1 and recovering said antibody.

17. A method for producing an antibody, comprising the step of immunizing an animal with the protein of claim 7 and recovering said antibody.

18. A method for detecting CD8 receptors, comprising the steps of:

(a) contacting a sample containing CD8 receptors with the protein of claim 1; and

(b) detecting the CD8-protein complex.

19. A method for detecting CD8 receptors, comprising the steps of:

(a) contacting a sample containing CD8 receptors with the protein of claim 7; and

(b) detecting the CD8-protein complex.

20. A water soluble protein encoded by a transcript of a human MHC HLA-G gene, wherein said transcript comprises in succession from the 5' end to the 3' end:

a sequence encoding the signal peptide;

a sequence encoding the .alpha.1 domain;

a sequence encoding the .alpha.3 domain, and

intron 4,

said transcript not including a sequence encoding the transmembrane domain.

21. A protein encoded by a transcript of the human MHC HLA-G gene, wherein said transcript comprises in succession from the 5' end to the 3' end:

a sequence encoding the signal peptide;

a sequence encoding the .alpha.1 domain;

a sequence encoding the .alpha.2 domain;

intron 4;

a sequence encoding the transmembrane domain;

a sequence encoding the cytoplasmic domain located on the 3' side of said sequence encoding the transmembrane domain.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France94 03179Mar 18, 1994

Details for Patent 5,856,442

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Commissariat a l\'Energie Atomique (Paris, FR) 2016-01-05 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Commissariat a l\'Energie Atomique (Paris, FR) 2016-01-05 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Commissariat a l\'Energie Atomique (Paris, FR) 2016-01-05 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
McKesson
Mallinckrodt
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.